Targacept (TRGT) Announces Positive Top-Line Results From Phase II Study of AZD3480 in Adult ADHD
More News related to TRGT
- Targacept (TRGT) To Be Listed on NASDAQ's Biotechnology Index (NBI)
- Targacept Added to NASDAQ Biotechnology Index
- Semi-Annual Changes to the NASDAQ Biotechnology Index
- Targacept to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Targacept (TRGT) Tops Q3 Views
Targacept, Inc. (NASDAQ: TRGT) announced preliminary results showing that AZD3480 (TC-1734) met the primary outcome measure in a Phase II clinical study in adults with attention deficit/hyperactivity disorder (ADHD).
In the study, adult subjects received in random order daily doses of 5mg of AZD3480, 50mg of AZD3480 and placebo, each for two weeks with the dosing periods separated by a three-week washout period. At 50mg AZD3480, subjects showed statistically significant (p < .01) improvement in symptoms of ADHD as measured by the study's primary outcome measure, total symptom score on the Conners Adult ADHD Rating Scale - Investigator Rating (CAARS-INV). Data from the study on CAARS-INV.
Statistically significant results were also achieved at 50mg AZD3480 on a number of secondary outcome measures in the study, including Stop Signal Reaction Time, a computerized assessment of behavioral inhibition, which is a core cognitive deficit of ADHD.
AZD3480 was well tolerated in the study, and there were no serious adverse events.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
